In a filing, Regulus Therapeutics Inc revealed its Chief Executive Officer Hagan Joseph P acquired Company’s shares for reported $54260.0 on Jan 30 ’25. In the deal valued at $1.09 per share,50,000 shares were bought. As a result of this transaction, Hagan Joseph P now holds 260,808 shares worth roughly $0.46 million.
Then, BALTIMORE DAVID bought 19,610 shares, generating $20,787 in total proceeds. Upon buying the shares at $1.06, the Director now owns 22,169 shares.
Before that, Aker Christopher Ray sold 38,547 shares. Regulus Therapeutics Inc shares valued at $48,693 were divested by the Sr. VP & General Counsel at a price of $1.26 per share. As a result of the transaction, Aker Christopher Ray now holds 54,634 shares, worth roughly $95609.5.
Wells Fargo upgraded its Regulus Therapeutics Inc [RGLS] rating to an Overweight from a an Equal weight in a research note published on March 27, 2025; the price target was increased to $6 from $3. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in early August with a ‘”an Outperform”‘ rating. Leerink Partners began covering RGLS with “an Outperform” recommendation on March 18, 2024. B. Riley FBR Inc. started covering the stock on March 28, 2018. It rated RGLS as “a Neutral”.
Price Performance Review of RGLS
On Monday, Regulus Therapeutics Inc [NASDAQ:RGLS] saw its stock jump 1.16% to $1.75. Over the last five days, the stock has gained 21.53%. Regulus Therapeutics Inc shares have risen nearly 10.76% since the year began. Nevertheless, the stocks have fallen -39.24% over the past one year. While a 52-week high of $2.91 was reached on 03/27/25, a 52-week low of $0.83 was recorded on 01/29/25. SMA at 50 days reached $1.2992, while 200 days put it at $1.5527.
Levels Of Support And Resistance For RGLS Stock
The 24-hour chart illustrates a support level at 1.6600, which if violated will result in even more drops to 1.5700. On the upside, there is a resistance level at 1.8400. A further resistance level may holdings at 1.9300. The Relative Strength Index (RSI) on the 14-day chart is 67.52, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.2150, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 38.46%. Stochastics %K at 50.00% indicates the stock is a holding.
How much short interest is there in Regulus Therapeutics Inc?
A steep rise in short interest was recorded in Regulus Therapeutics Inc stocks on 2025-03-14, growing by 8034.0 shares to a total of 2.04 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 2.03 million shares. There was a rise of 0.39%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on January 05, 2018 when Leerink Partners began covering the stock and recommended ‘”an Outperform”‘ rating along with a $2 price target.
